Compare MPLX LP (MPLX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Recursion Pharmaceuticals Inc — how do they compare? MPLX LP trades at $59.35 (market cap $60.12B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.81B). The key difference: MPLX LP is far larger — about 33.2× Recursion Pharmaceuticals Inc's market cap, and MPLX LP pays a 7.26% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MPLX | RXRX | |
|---|---|---|
Market Cap | $60.12B | $1.81B |
Sector | Technology | Health |
52-Week High | $60.51 | $6.79 |
52-Week Low | $47.80 | $2.84 |
Enterprise Value | $85.22B | $1.33B |
Dividend Yield | 7.26% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
